Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Theravance Biopharma (TBPH) over the last 12 years, with Q3 2025 value amounting to $4.1 million.

  • Theravance Biopharma's Non Operating Income rose 19250.88% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 2773.01%. This contributed to the annual value of $4.9 million for FY2024, which is 4645.68% down from last year.
  • Per Theravance Biopharma's latest filing, its Non Operating Income stood at $4.1 million for Q3 2025, which was up 19250.88% from $1.5 million recorded in Q2 2025.
  • Theravance Biopharma's 5-year Non Operating Income high stood at $4.1 million for Q3 2025, and its period low was -$375000.0 during Q1 2022.
  • Over the past 5 years, Theravance Biopharma's median Non Operating Income value was $1.4 million (recorded in 2024), while the average stood at $1.6 million.
  • As far as peak fluctuations go, Theravance Biopharma's Non Operating Income crashed by 11602.74% in 2021, and later skyrocketed by 176144.58% in 2022.
  • Over the past 5 years, Theravance Biopharma's Non Operating Income (Quarter) stood at $338000.0 in 2021, then skyrocketed by 1001.18% to $3.7 million in 2022, then crashed by 50.38% to $1.8 million in 2023, then plummeted by 51.06% to $904000.0 in 2024, then surged by 357.85% to $4.1 million in 2025.
  • Its Non Operating Income stands at $4.1 million for Q3 2025, versus $1.5 million for Q2 2025 and $939000.0 for Q1 2025.